Literature DB >> 25484924

Risk of healthcare associated infections in HIV positive patients.

Mohammed Mitha1, E Yoko Furuya2, Elaine Larson3.   

Abstract

HIV positive patients are a high risk population due to the alteration in their immune status. Health-care associated infections (HAI) have not been well described in this population, with some risk factors reported inconsistently in the literature. The aim of this study was to describe the epidemiology as well as the underlying risk factors for HAI, specifically urinary tract infection (UTI), bloodstream infection (BSI) and respiratory tract infection (RTI). This was a retrospective cohort study conducted at an academic health system in New York City which included three hospitals over a two year period from 2006 to 2008. There were 3,877 HIV positive patient discharges in 1,911 patients. There were a total of 142 UTI, 106 BSI, and 100 RTI. The incidence rates were 4.35 for UTI, 3.16 for BSI and 2.98 for RTI. CD4 count and antiretroviral therapy were not associated with HAI. Significant predictors of UTI included urinary catheter, length of stay, female gender, steroids and trimethoprim-sulphamethoxazole (TMP-SMX); of BSI were steroids and TMP-SMX; and RTI were mechanical ventilation, steroids and TMP-SMX. Multivariable analysis indicated that TMP-SMX was significantly associated with an increased risk of infection for all three types of HAI [BSI odds ratio 2.55, 95% confidence interval (1.22-5.34); UTI odds ratio 3.1, 95% confidence interval (1.41-7.22); RTI odds ratio 5.15, 95% confidence interval (1.70-15.62)]. HIV positive patients are at significant risk for developing HAI, but the risk factors differ depending on the specific type of infection. The fact that TMP-SMX is a risk factor in these patients warrants further research as this may have significant health policy implications.

Entities:  

Keywords:  HIV; Health care associated infections; trimethoprim sulphamethoxazole

Year:  2014        PMID: 25484924      PMCID: PMC4254806          DOI: 10.1177/1757177414548694

Source DB:  PubMed          Journal:  J Infect Prev        ISSN: 1757-1782


  17 in total

1.  Incidence and epidemiology of nosocomial infections in patients infected with human immunodeficiency virus.

Authors:  U Frank; F D Daschner; G Schulgen; J Mills
Journal:  Clin Infect Dis       Date:  1997-08       Impact factor: 9.079

Review 2.  Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis.

Authors:  Amitabh B Suthar; Reuben Granich; Jonathan Mermin; Annelies Van Rie
Journal:  Bull World Health Organ       Date:  2011-10-24       Impact factor: 9.408

Review 3.  Nosocomial colonization and infection in persons infected with human immunodeficiency virus.

Authors:  D E Craven; K A Steger; L R Hirschhorn
Journal:  Infect Control Hosp Epidemiol       Date:  1996-05       Impact factor: 3.254

4.  Nosocomial bloodstream infections among human immunodeficiency virus-infected patients: incidence and risk factors.

Authors:  Nicola Petrosillo; Pierluigi Viale; Emanuele Nicastri; Claudio Arici; Enrico Bombana; Alberto Casella; Francesco Cristini; Michele De Gennaro; Ferdinando Dodi; Andrea Gabbuti; Gianni Gattuso; Laura Irato; Paolo Maggi; Federico Pallavicini; Angelo Pan; Mario Pantaleoni; Giuseppe Ippolito
Journal:  Clin Infect Dis       Date:  2002-01-25       Impact factor: 9.079

5.  Estimating health care-associated infections and deaths in U.S. hospitals, 2002.

Authors:  R Monina Klevens; Jonathan R Edwards; Chesley L Richards; Teresa C Horan; Robert P Gaynes; Daniel A Pollock; Denise M Cardo
Journal:  Public Health Rep       Date:  2007 Mar-Apr       Impact factor: 2.792

6.  Using electronically available inpatient hospital data for research.

Authors:  Mandar Apte; Matthew Neidell; E Yoko Furuya; David Caplan; Sherry Glied; Elaine Larson
Journal:  Clin Transl Sci       Date:  2011-10       Impact factor: 4.689

7.  Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America.

Authors:  Henry Masur; Jonathan E Kaplan; King K Holmes
Journal:  Ann Intern Med       Date:  2002-09-03       Impact factor: 25.391

8.  Nosocomial bloodstream infections in HIV-infected patients: attributable mortality and extension of hospital stay.

Authors:  M Tumbarello; E Tacconelli; K G Donati; F Leone; G Morace; R Cauda; L Ortona
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-12-15

9.  Nosocomial infections among HIV-positive and HIV-negative patients in a Brazilian infectious diseases unit.

Authors:  Maria Clara Padoveze; Plínio Trabasso; Maria Luiza Moretti Branchini
Journal:  Am J Infect Control       Date:  2002-10       Impact factor: 2.918

10.  Nosocomial infection rate as a function of human immunodeficiency virus type 1 status in hemophiliacs.

Authors:  D J Weber; P R Becherer; W A Rutala; G P Samsa; M B Wilson; G C White
Journal:  Am J Med       Date:  1991-09-16       Impact factor: 4.965

View more
  4 in total

Review 1.  Epidemiology and management of healthcare-associated bloodstream infections in non-neutropenic immunosuppressed patients: a review of the literature.

Authors:  Nursel Calik Basaran; Sibel Ascioglu
Journal:  Ther Adv Infect Dis       Date:  2017-10-17

2.  Risk Factors and Temporal Trends of Hospital-Acquired Infections (HAIs) Among HIV Positive Patients in Urban New York City Hospitals: 2006 to 2014.

Authors:  Christophe T Tchakoute; Jianfang Liu; Bevin Cohen; Elaine Larson
Journal:  Rev Recent Clin Trials       Date:  2017

3.  The impact of HIV diagnosis on length of hospital stay in New York City, NY, USA.

Authors:  Tawandra L Rowell-Cunsolo; Jianfang Liu; Yanhan Shen; Amber Britton; Elaine Larson
Journal:  AIDS Care       Date:  2018-01-17

4.  Bloodstream infections in patients living with HIV in the modern cART era.

Authors:  L Taramasso; F Liggieri; G Cenderello; F Bovis; B Giannini; A Mesini; M Giacomini; G Cassola; C Viscoli; A Di Biagio
Journal:  Sci Rep       Date:  2019-04-01       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.